At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01093 CSPC PHARMA
Trading 10-15 10:10:00
9.005
+0.195
+2.21%
High9.075Low8.720Vol20.84M
Open8.810D1 Closing8.810Amplitude4.03%
Mkt Cap103.76BTradable Cap103.76BTotal Shares11.52B
T/O185.73MT/O Rate0.18%Tradable Shares11.52B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜CSPC PHARMA Falls 3.09% in Regular Trading, Recent R&D Updates Fail to Prevent Sector Weakness
Market Focus  ·  10-14 13:42
Movement Alert｜CSPC PHARMA Falls 3.09% in Regular Trading, Recent R&D Updates Fail to Prevent Sector Weakness
Movement Alert｜CSPC PHARMA Falls 3.07% in Regular Trading, Innovative Drug Sector Retreats After Holiday
Market Focus  ·  10-09
Movement Alert｜CSPC PHARMA Falls 3.07% in Regular Trading, Innovative Drug Sector Retreats After Holiday
CSPC Pharma Presents Data from Cervical Cancer Study at Gynecologic Cancer Society Meeting
MT Newswires Live  ·  10-08
CSPC Pharma Presents Data from Cervical Cancer Study at Gynecologic Cancer Society Meeting
CSPC Pharma Unveils Phase I Data for SYS6002 Monotherapy in Advanced Cervical Cancer at IGCS 2026 Rapid Oral Presentation
Stock News  ·  10-08
CSPC Pharma Unveils Phase I Data for SYS6002 Monotherapy in Advanced Cervical Cancer at IGCS 2026 Rapid Oral Presentation
CSPC Pharmaceutical Group Stock Sheds 5.4% in Hong Kong, Underperforms Competitors
Dow Jones  ·  10-08
CSPC Pharmaceutical Group Stock Sheds 5.4% in Hong Kong, Underperforms Competitors
Movement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout
Market Focus  ·  10-08
Movement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout
CSPC Pharmaceutical Group Stock Rises 1.5% in Hong Kong, Underperforms Competitors
Dow Jones  ·  10-06
CSPC Pharmaceutical Group Stock Rises 1.5% in Hong Kong, Underperforms Competitors
CSPC Pharma to Present Updates from Eight Trials at European Oncology Conference
MT Newswires Live  ·  10-05
CSPC Pharma to Present Updates from Eight Trials at European Oncology Conference
CSPC Pharma to Present Eight Oncology Trial Updates, Including Two Late-Breaking Abstracts, at ESMO 2026
Bulletin Express  ·  10-05
CSPC Pharma to Present Eight Oncology Trial Updates, Including Two Late-Breaking Abstracts, at ESMO 2026
CSPC Pharma to Unveil Eight New Clinical Trial Advances at 2026 ESMO Congress
Stock News  ·  10-05
CSPC Pharma to Unveil Eight New Clinical Trial Advances at 2026 ESMO Congress
CSPC PHARMA Maintains 11.52 Billion Shares Outstanding in September; 1.15 Billion Options Could Add 10% Dilution
Bulletin Express  ·  10-02
CSPC PHARMA Maintains 11.52 Billion Shares Outstanding in September; 1.15 Billion Options Could Add 10% Dilution
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Movement Alert｜CSPC PHARMA Falls 3.13% in Regular Trading, Trading at HK$9.735
Market Focus  ·  10-02
Movement Alert｜CSPC PHARMA Falls 3.13% in Regular Trading, Trading at HK$9.735
CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates
Simply Wall St.  ·  10-01
CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates
CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study
MT Newswires Live  ·  10-01
CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study
CSPC Pharma Announces Positive Phase III Results for Weekly GLP-1 Candidate TG103 in Chinese Type 2 Diabetes Patients
Bulletin Express  ·  09-30
CSPC Pharma Announces Positive Phase III Results for Weekly GLP-1 Candidate TG103 in Chinese Type 2 Diabetes Patients
CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026
Stock News  ·  09-30
CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026
CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  09-30
CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors
AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
Stock News  ·  09-30
AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines
Stock News  ·  09-30
CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines

Introduction

Company Name.
CSPC PHARMA
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CSPC Pharmaceutical Group Ltd is a company primarily engaged in the production and sales of pharmaceuticals. The Company's main businesses include finished drug manufacturing, bulk product business, functional food and other businesses. The Company's products mainly cover the nervous system, anti-tumor, anti-infective, cardiovascular, respiratory system, digestive and metabolic, and other therapeutic areas. The Company conducts its businesses in domestic and overseas markets.
Issue price:
--